Equity Overview
Price & Market Data
Price: $3.33
Daily Change: +$0.08 / 2.40%
Range: $3.22 - $3.44
Market Cap: $170,066,096
Volume: 47,593
Performance Metrics
1 Week: -11.90%
1 Month: 10.26%
3 Months: -38.33%
6 Months: -57.95%
1 Year: -61.90%
YTD: -49.92%
Company Details
Employees: 57
Sector: Health technology
Industry: Biotechnology
Country: Canada
Details
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.